Sector: MedicalXenoPort, Inc. (NASDAQ: XNPT)
Headlines
- GlaxoSmithKline and XenoPort Announce Extension of GSK1838262 (XP13512) FDA Review Date to February 9, 2010
Nov 06, 2009 08:15 PM | GSK, XNPT
- XenoPort Reports Third Quarter Financial Results
Nov 03, 2009 04:05 PM | XNPT
- XenoPort to Release Third Quarter Financial Results on November 3, 2009
Oct 29, 2009 01:30 PM | XNPT
- XenoPort Announces Initiation of a Phase 2b Clinical Trial of Arbaclofen Placarbil in Patients with Gastroesophageal Reflux Disease
Oct 19, 2009 06:30 AM | XNPT
- This Fall Will Be Crazy For These Biotech Stocks
Oct 16, 2009 02:55 PM | ACOR, AMGN, CADX, GTXI, THRX, XNPT
- Positive Phase II Results for GSK1838262 (XP13512) Reported for Subjects with Post-Herpetic Neuralgia and a History of Inadequate Response to Gabapentin
Oct 05, 2009 06:30 AM | GSK, XNPT
- Positive Phase IIb Results for GSK1838262 (XP13512) Reported for Neuropathic Pain Associated with Post-Herpetic Neuralgia
Sep 17, 2009 06:00 AM | GSK, XNPT
- XenoPort to Present at Upcoming Conferences
Sep 09, 2009 01:30 PM | BAC, MS, XNPT
- XenoPort Reports Preliminary Results From a Safety and Tolerability Trial of Arbaclofen Placarbil in Patients With Acute Back Spasms
Sep 08, 2009 06:00 AM | XNPT
- CORRECTING and REPLACING XenoPort Appoints Dennis Fenton to Board
Aug 13, 2009 12:51 PM | AMGN, XNPT
- XenoPort Reports Second Quarter Financial Results
Aug 05, 2009 04:21 PM | XNPT
- XenoPort Announces Astellas’ Plans to File an NDA for XP13512 in Japan
Aug 03, 2009 06:32 AM | XNPT
- XenoPort to Release Second Quarter Financial Results on August 5, 2009
Jul 23, 2009 01:31 PM | XNPT
- XenoPort Announces Pricing of Public Offering of Common Stock
Jul 08, 2009 10:00 AM | XNPT
- XenoPort Announces Proposed Public Offering of Common Stock
Jul 07, 2009 04:56 PM | XNPT
- XenoPort Reports Positive Results from a Phase 2 Trial of Arbaclofen Placarbil in Spinal Cord Injury Patients with Spasticity
Jun 30, 2009 06:31 AM | XNPT
- XenoPort to Present at the Piper Jaffray Fourth Annual Europe Conference
Jun 12, 2009 10:31 AM | XNPT
- XenoPort to Present at the Goldman Sachs 30th Annual Global Healthcare Conference
Jun 03, 2009 05:54 PM | XNPT
- XenoPort Data Presented at Digestive Disease Week Meeting Demonstrates Arbaclofen Placarbil Monotherapy Reduces Heartburn and Regurgitation in GERD Patients Previously Treated with PPIs
Jun 01, 2009 05:02 PM | XNPT
- XenoPort to Present at the Deutsche Bank 34th Annual Health Care Conference
May 13, 2009 02:01 PM | XNPT
- Form 4 Cundy Kenneth C For: Oct 06 (10K)
Oct 07, 2009 07:39 PM
- Form 4 Cundy Kenneth C For: Sep 17 (10K)
Sep 22, 2009 02:18 PM
- Form 4 FENTON DENNIS M For: Aug 12 (10K)
Aug 14, 2009 06:48 PM
- Form 3 FENTON DENNIS M For: Aug 12 (10K)
Aug 14, 2009 06:46 PM
- Form 4 Angotti Vincent For: Aug 10 (10K)
Aug 12, 2009 08:27 PM
- Form 4 Stamler David A For: Aug 10 (10K)
Aug 12, 2009 08:27 PM
- Form 4 Freund John Gordon For: Jul 08 (10K)
Jul 11, 2009 01:21 PM
- Form 4 Cundy Kenneth C For: Jun 11 (10K)
Jun 15, 2009 06:43 PM
- Form 4 XENOPORT INC For: May 07 Filed by: WIERENGA WENDALL (10K)
May 08, 2009 06:01 PM
- Form 4 NUSSBACHER KENNETH J For: May 07 (10K)
May 08, 2009 06:00 PM
Analyst Ratings
Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
Share Performance
|
Period
|
XNPT
|
Compare to S&P
|
| YTD |
-33.37 %
|
-41.92 %
|
| 4 Weeks |
-15.73 %
|
-16.63 %
|
| 12 Weeks |
-18.88 %
|
-20.90 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: -660.00 %
|
|
EPS Growth in Last Year: -55.10 %
|
|
Sales Growth in Last Quarter: -93.03 %
|
|
Sales Growth in Last Quarter: -84.13 %
|
|
